CDC Website CDC Website

To Join the NPIN community or

Home » Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, and preclinical and/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. 

Funding Organization
Funding Category
Support Types
Locations
National
Eligible Organizations
Number of Awards Given
Contingent upon NIH appropriations.
Award Amount Notes
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Application Due Date
1/8/20
Project Start Date
7/1/20
Application Contact
Ann
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
United States
240-669-2988
adevine@niaid.nih.gov
Technical Contact
Daniel
Frank, Ph.D
Chief, Gene Regulation Section
Daniel.Frank@nih.gov
United States
301-761-6256
Subjects
Audiences

Fund Number: 

5497

Fund ID: 

PAR-19-357

Last modified: 

9/4/19